Opportunity Information: Apply for PA 12 294
Apply for PA 12 294
- The National Institutes of Health in the education health sector is offering a public funding opportunity titled "Drug Abuse Aspects of HIV/AIDS (R03)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.279 Drug Abuse and Addiction Research Programs.
- This funding opportunity was created on Sep 25, 2012 and posted on Sep 25, 2012.
- Applicants must submit their applications by Jan 7, 2016. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- Each selected applicant is eligible to receive up to $50,000.00 in funding.
- Eligible applicants include: Others (see text field entitled Additional Information on Eligibility for clarification) Public and State controlled institutions of higher education For profit organizations other than small businesses County governments Small businesses City or township governments State governments Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education Native American tribal governments (Federally recognized) Public housing authorities/Indian housing authorities Independent school districts Private institutions of higher education Special district governments Native American tribal organizations (other than Federally recognized tribal governments).
- Other Eligible Applicants include the following Alaska Native and Native Hawaiian Serving Institutions Eligible Agencies of the Federal Government Faith based or Community based Organizations Hispanic serving Institutions Historically Black Colleges and Universities (HBCUs) Indian/Native American Tribal Governments (Other than Federally Recognized) Non domestic (non U.S.) Entities (Foreign Organizations) Regional Organizations Tribally Controlled Colleges and Universities (TCCUs) U.S. Territory or Possession Non domestic (non U.S.) Entities (Foreign Institutions) are eligible to apply. Non domestic (non U.S.) components of U.S. Organizations are eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are allowed.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Opportunity Summary:
The Drug Abuse Aspects of HIV/AIDS (R03) funding opportunity (PA 12-294) is a National Institute on Drug Abuse (NIDA), National Institutes of Health (NIH) small grant program designed to support focused, limited-scope research projects that explore how drug use and addiction intersect with HIV/AIDS. The announcement is aimed at studies that clarify and address the ways drug-related behaviors and substance use disorders contribute to HIV risk and transmission, influence the course of HIV disease, and shape the broader health and social consequences experienced by people who use drugs and their partners. In practical terms, it is looking for smaller, well-defined projects that can generate preliminary data, test a targeted idea, or develop a method or intervention that can later be expanded through larger NIH mechanisms.
The core scientific emphasis is on the drug abuse aspects of HIV/AIDS across several connected areas. One major area is drug-related risk behavior, including both injection and non-injection drug use, and how those behaviors affect HIV acquisition and onward transmission among people who use drugs and their sexual partners. Another major area is the interaction between addiction and HIV disease, including how ongoing substance use, withdrawal, or treatment engagement may affect HIV progression, adherence to antiretroviral therapy, viral suppression, and overall clinical outcomes. The FOA also highlights drug use and HIV-related comorbidities and consequences, which can include mental health conditions, viral hepatitis and other co-infections, cardiovascular or neurologic complications, social instability, stigma, and other factors that complicate prevention and care.
In addition to describing these topic areas, the announcement makes clear what kinds of research products it wants to encourage. It specifically calls for work that can identify and predict changes in HIV/AIDS epidemiology among injection and non-injection drug users and their sexual partners, which can include surveillance-related analyses, modeling, or other approaches that help anticipate emerging trends and guide public health responses. It also calls for the development and testing of interventions for both primary and secondary HIV prevention. Primary prevention in this context generally means preventing HIV acquisition, while secondary prevention focuses on reducing transmission risk and improving outcomes among people already living with HIV. Importantly, the FOA explicitly includes drug treatment interventions as a prevention strategy, reflecting the idea that improving access to and engagement in evidence-based substance use treatment can reduce risk behaviors and improve HIV care outcomes. It also encourages research aimed at improving HIV testing, counseling, and treatment services for individuals living with HIV/AIDS, particularly where substance use creates barriers to service uptake or retention.
The FOA additionally supports basic and mechanistic research that examines HIV infection and AIDS pathogenesis in the context of drug abuse and addiction. This includes studies that look at biological mechanisms by which substances (or the physiologic states associated with addiction) may influence immune function, inflammation, viral replication dynamics, susceptibility to infection, or disease progression. The intent is to better understand how drug exposure and addiction-related factors may alter the biology of HIV and AIDS, which can inform both clinical approaches and the design of more effective prevention and treatment strategies.
From an administrative and eligibility perspective, this is a discretionary grant opportunity using the NIH R03 small grant mechanism. The listed award ceiling is $50,000. There is no cost sharing or matching requirement. The opportunity was posted and created on September 25, 2012, with an original and final closing date of January 7, 2016, and it was archived on February 7, 2016. While the archived status means it is no longer accepting applications, the summary still provides a clear picture of NIDA priorities at the time and the kinds of projects that were considered a good fit for an R03 in this scientific area.
Eligibility is broad and includes many organization types: public and private institutions of higher education, nonprofit organizations (with or without 501(c)(3) status), for-profit organizations (including small businesses and other for-profits), and a range of governmental entities (state, county, city or township, special district governments), as well as independent school districts and public housing authorities/Indian housing authorities. The FOA also specifies additional eligible applicants and organizational categories such as Historically Black Colleges and Universities (HBCUs), Hispanic-serving institutions, tribally controlled colleges and universities, Alaska Native and Native Hawaiian serving institutions, and faith-based or community-based organizations. Notably, non-U.S. entities and foreign institutions are eligible to apply, non-U.S. components of U.S. organizations may apply, and foreign components (as defined by NIH policy) are permitted, which signals an openness to international or cross-border work where it can advance the goals of understanding and reducing the HIV burden connected to drug use.
For reference and official details, the announcement pointed applicants to the NIH Grants Guide page at http://grants.nih.gov/grants/guide/pa-files/PA-12-294.html and provided NIH Office of Extramural Research (OER) webmaster contacts for access or linking issues (FBOWebmaster@OD.NIH.GOV).
FAQs: Drug Abuse Aspects of HIV/AIDS (R03) - PA 12-294
What is the Drug Abuse Aspects of HIV/AIDS (R03) opportunity?
It is a National Institute on Drug Abuse (NIDA), National Institutes of Health (NIH) funding opportunity that used the NIH R03 small grant mechanism to support focused, limited-scope research on how drug use and addiction intersect with HIV/AIDS.
What is the goal of this funding opportunity?
The goal is to support smaller, well-defined projects that clarify and address how drug-related behaviors and substance use disorders contribute to HIV risk and transmission, influence the course of HIV disease, and shape health and social consequences for people who use drugs and their partners.
What types of projects were considered a good fit for an R03 under this announcement?
The announcement emphasized limited-scope projects that can generate preliminary data, test a targeted idea, or develop a method or intervention that could later be expanded through larger NIH funding mechanisms.
What scientific areas does the announcement emphasize?
The core emphasis is on the drug abuse aspects of HIV/AIDS, including drug-related risk behavior, interactions between addiction and HIV disease, and HIV-related comorbidities and consequences that are affected by substance use and addiction.
Does the FOA cover both injection and non-injection drug use?
Yes. It specifically includes drug-related risk behavior involving both injection and non-injection drug use and how those behaviors affect HIV acquisition and transmission among people who use drugs and their sexual partners.
What kinds of HIV risk and transmission questions are relevant?
Relevant topics include how drug-related behaviors contribute to HIV acquisition and onward transmission, including impacts on people who use drugs and their sexual partners.
Does the announcement include research on how substance use affects HIV treatment outcomes?
Yes. It highlights research on interactions between addiction and HIV disease, including how ongoing substance use, withdrawal, or treatment engagement may affect HIV progression, adherence to antiretroviral therapy, viral suppression, and overall clinical outcomes.
What comorbidities and broader consequences are within scope?
The scope includes drug use and HIV-related comorbidities and consequences such as mental health conditions, viral hepatitis and other co-infections, cardiovascular or neurologic complications, social instability, stigma, and other factors that complicate prevention and care.
Does the FOA encourage research that predicts changes in HIV epidemiology?
Yes. It specifically calls for work that can identify and predict changes in HIV/AIDS epidemiology among injection and non-injection drug users and their sexual partners, including approaches such as surveillance-related analyses or modeling.
Are intervention studies supported, and what kinds?
Yes. The FOA calls for development and testing of interventions for primary and secondary HIV prevention in the context of drug use and addiction.
What is meant by primary vs. secondary HIV prevention in this FOA?
Primary prevention refers to preventing HIV acquisition. Secondary prevention focuses on reducing transmission risk and improving outcomes among people already living with HIV.
Are drug treatment interventions considered part of HIV prevention under this announcement?
Yes. The FOA explicitly includes drug treatment interventions as a prevention strategy, reflecting the role of access to and engagement in evidence-based substance use treatment in reducing risk behaviors and improving HIV care outcomes.
Does the FOA support work to improve HIV testing, counseling, and treatment services?
Yes. It encourages research aimed at improving HIV testing, counseling, and treatment services for individuals living with HIV/AIDS, particularly where substance use creates barriers to service uptake or retention.
Is basic or mechanistic research included, or only applied/public health research?
Basic and mechanistic research is included. The FOA supports studies examining HIV infection and AIDS pathogenesis in the context of drug abuse and addiction.
What kinds of biological mechanisms are mentioned as examples?
Examples include mechanisms by which substances or addiction-related physiological states may influence immune function, inflammation, viral replication dynamics, susceptibility to infection, or disease progression.
What grant mechanism was used for this opportunity?
This was a discretionary NIH grant opportunity using the R03 small grant mechanism.
What was the maximum award amount listed?
The listed award ceiling was $50,000.
Is cost sharing or matching required?
No. The announcement stated there was no cost sharing or matching requirement.
When was the opportunity posted?
It was posted and created on September 25, 2012.
What were the application closing dates?
The original and final closing date listed was January 7, 2016.
Is this funding opportunity still accepting applications?
No. It was archived on February 7, 2016, which indicates it is no longer accepting applications.
Why is the archived opportunity still useful to review?
Even though it is archived, the summary describes NIDA priorities at the time and the kinds of small, focused projects that were considered a good fit for an R03 in this scientific area.
Who was the sponsoring agency?
The sponsoring institute was the National Institute on Drug Abuse (NIDA), part of the National Institutes of Health (NIH).
What types of organizations were eligible to apply?
Eligibility was broad and included public and private institutions of higher education, nonprofit organizations (with or without 501(c)(3) status), for-profit organizations (including small businesses), and governmental entities such as state, county, city or township, and special district governments, as well as independent school districts and public housing authorities/Indian housing authorities.
Were minority-serving institutions and community-based organizations included in eligibility?
Yes. The FOA listed categories including Historically Black Colleges and Universities (HBCUs), Hispanic-serving institutions, tribally controlled colleges and universities, Alaska Native and Native Hawaiian serving institutions, and faith-based or community-based organizations.
Could foreign or non-U.S. entities apply?
Yes. The FOA indicated that non-U.S. entities and foreign institutions were eligible to apply. It also permitted non-U.S. components of U.S. organizations and allowed foreign components as defined by NIH policy.
Where could applicants find the official announcement details?
The announcement directed applicants to the NIH Grants Guide page at http://grants.nih.gov/grants/guide/pa-files/PA-12-294.html.
Who was listed as a contact for access or linking issues?
The NIH Office of Extramural Research (OER) webmaster contact provided was FBOWebmaster@OD.NIH.GOV.
Browse more opportunities from the same agency: National Institutes of Health
Browse more opportunities from the same category: Education Health
Next opportunity: Drug Abuse Aspects of HIV/AIDS (R21)
Previous opportunity: 2013 PTT Grants
USGrants.org Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for PA 12 294
[Watch] how do funding administrators access proposals?
Applicants also applied for:
Applicants who have applied for this opportunity (PA 12 294) also looked into and applied for these:
| Funding Opportunity |
|---|
| Drug Abuse Aspects of HIV/AIDS (R21) Apply for PA 12 295 Funding Number: PA 12 295 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| Mechanism for Time Sensitive Drug Abuse Research (R21) Apply for PAR 12 297 Funding Number: PAR 12 297 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| Cancer Center Support Grants (CCSGs) for NCI designated Cancer Centers (P30) Apply for PAR 12 298 Funding Number: PAR 12 298 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| FY 2013 American Schools and Hospitals Abroad (ASHA) Program Worldwide Apply for APS ASHA 13 000001 Funding Number: APS ASHA 13 000001 Agency: Agency for International Development Category: Education Health Funding Amount: $2,000,000 |
| NLM Grants for Scholarly Works in Biomedicine and Health (G13) Apply for PAR 13 014 Funding Number: PAR 13 014 Agency: National Institutes of Health Category: Education Health Funding Amount: $50,000 |
| Prescription Drug Abuse (R01) Apply for PA 13 015 Funding Number: PA 13 015 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Prescription Drug Abuse (R21) Apply for PA 13 016 Funding Number: PA 13 016 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| Early Stage Innovative Molecular Analysis Technology Development for Cancer Research (R21) Apply for RFA CA 13 001 Funding Number: RFA CA 13 001 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| Validation and Advanced Development of Emerging Molecular Analysis Technologies for Cancer Research (R33) Apply for RFA CA 13 002 Funding Number: RFA CA 13 002 Agency: National Institutes of Health Category: Education Health Funding Amount: $300,000 |
| Early Stage Development of Innovative Technologies for Biospecimen Science (R21) Apply for RFA CA 13 003 Funding Number: RFA CA 13 003 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| Validation and Advanced Development of Emerging Technologies for Biospecimen Science (R33) Apply for RFA CA 13 004 Funding Number: RFA CA 13 004 Agency: National Institutes of Health Category: Education Health Funding Amount: $300,000 |
| Limited Competition Palliative Care Research Co Operative (PCRC) (U24) Apply for RFA NR 13 004 Funding Number: RFA NR 13 004 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Utilizing the PLCO Biospecimens Resource to Bridge Gaps in Cancer Etiology and Early Detection Research (U01) Apply for PAR 13 036 Funding Number: PAR 13 036 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Exceptional Unconventional Research Enabling Knowledge Acceleration (EUREKA) for Neuroscience and Disorders of the Nervous System (R01) Apply for RFA NS 13 007 Funding Number: RFA NS 13 007 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| AIDS and Cancer Specimen Resource (ACSR) (UM1) Apply for RFA CA 13 005 Funding Number: RFA CA 13 005 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Drug Discovery for Nervous System Disorders (R01) Apply for PAR 13 048 Funding Number: PAR 13 048 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Drug Discovery for Nervous System Disorders (R21) Apply for PAR 13 049 Funding Number: PAR 13 049 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| Pain in Aging (R01) Apply for PA 13 058 Funding Number: PA 13 058 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Pain in Aging (R21) Apply for PA 13 059 Funding Number: PA 13 059 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| Pain in Aging (R03) Apply for PA 13 060 Funding Number: PA 13 060 Agency: National Institutes of Health Category: Education Health Funding Amount: $50,000 |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Subscribe to Leads
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "PA 12 294", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.